EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

Samantha Cambier(European Organisation for Research and Treatment of Cancer), Richard Sylvester(European Organisation for Research and Treatment of Cancer), Laurence Collette(European Organisation for Research and Treatment of Cancer), Paolo Gontero(Fondazione Ricerca Molinette), Maurizio Brausi, George van Andel(OLVG), Wim J. Kirkels(Erasmus MC), Fernando Calais da Silva(Hospital do Desterro), Willem Oosterlinck(Ghent University Hospital), Stephen M. Prescott(St James's University Hospital), Ziya Kırkalı(Dokuz Eylül University), Philip Powell(Freeman Hospital), Theo M. de Reijke(Academic Medical Center), Levent Türkeri(Marmara University), Sandra Collette(European Organisation for Research and Treatment of Cancer), Jorg R. Oddens(Jeroen Bosch Ziekenhuis)
European Urology
July 23, 2015
Cited by 634Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis